Olezarsen for Cardiovascular Disease
Trial Summary
Will I have to stop taking my current medications?
The trial requires participants to continue taking their standard-of-care lipid-lowering medications as per local guidelines.
What is known about the safety of Olezarsen for cardiovascular disease?
Olezarsen, also known as volanesorsen, has been studied for its ability to lower triglyceride levels, which are fats in the blood linked to heart disease. While the research primarily focuses on its effectiveness, it is being evaluated in clinical trials for safety, and no major safety concerns have been highlighted in the available studies.12345
What is the purpose of this trial?
This trial is testing olezarsen, a medication aimed at lowering blood fats, in people with high triglycerides who are at risk for heart disease. The medication works by reducing proteins and fats in the blood to help lower cholesterol and triglyceride levels.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive olezarsen or placebo by subcutaneous injection every 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Olezarsen
Olezarsen is already approved in United States, European Union for the following indications:
- adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)
- treatment of familial chylomicronemia syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ionis Pharmaceuticals, Inc.
Lead Sponsor
Dr. Brett P. Monia
Ionis Pharmaceuticals, Inc.
Chief Executive Officer since 2020
PhD in Pharmacology from the University of Pennsylvania, BSc in Molecular Biology and Analytical Chemistry from Stockton State College
Dr. Eric Bastings
Ionis Pharmaceuticals, Inc.
Chief Medical Officer
MD